Defunct Company
Total Trials
7
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,347
NCT02793687
Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy
Phase: Phase 3
Role: Lead Sponsor
Start: Mar 6, 2015
Completion: May 27, 2016
NCT06854601
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
Start: Jul 13, 2019
Completion: Jul 13, 2020
NCT06834490
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
Start: Nov 5, 2019
Completion: Dec 8, 2020
NCT06437626
The Study of Efficacy and Safety of Mexidol® in Stroke Therapy (MIR)
Start: Nov 18, 2019
Completion: Aug 18, 2023
NCT06903156
Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)
Phase: Phase 2
Start: Nov 15, 2021
Completion: Sep 7, 2023
NCT06221826
MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure
Phase: Phase 4
Start: Apr 17, 2023
Completion: Sep 12, 2023
NCT06437639
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
Start: Sep 15, 2023
Completion: Feb 2, 2024